JAK2 and acute lymphoblastic leukemia: However, this ruxolitinib persistence mechanism is not predicted to occur in JAK2r ALL as a recent study modelling acquired ruxolitinib resistance in JAK2r ALL in vitro identified emergent JAK inhibitor-resistant JAK2 point mutations (Downes et al., 2021).